Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clinical Trial
Official title:
Phase II Clinical Trial of Dasatinib First Line Therapy for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
The purpose of this study is to evaluate effectiveness of Dasatinib as the first line therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase in Japan.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01437202 -
Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia
|
N/A | |
| Completed |
NCT02896842 -
A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML
|
Phase 2 | |
| Withdrawn |
NCT02421926 -
Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)
|
||
| Completed |
NCT01768689 -
Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
|
N/A | |
| Not yet recruiting |
NCT02903277 -
National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent
|
N/A | |
| Completed |
NCT03090477 -
Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients
|
N/A | |
| Active, not recruiting |
NCT02885766 -
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene
|
Phase 1/Phase 2 | |
| Completed |
NCT01602952 -
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT02687425 -
Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia
|
Phase 2 | |
| Completed |
NCT00171223 -
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha
|
Phase 2 | |
| Recruiting |
NCT04877522 -
Asciminib Roll-over Study
|
Phase 4 | |
| Completed |
NCT01511289 -
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
|
Phase 3 | |
| Completed |
NCT02480608 -
Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)
|
Phase 1/Phase 2 | |
| Completed |
NCT02389972 -
Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study
|
N/A | |
| Completed |
NCT01774630 -
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
|
Phase 2 |